CN104610114B - The N-diamantane amides that one class alkoxyphenyl radical replaces and purposes thereof - Google Patents
The N-diamantane amides that one class alkoxyphenyl radical replaces and purposes thereof Download PDFInfo
- Publication number
- CN104610114B CN104610114B CN201510075722.8A CN201510075722A CN104610114B CN 104610114 B CN104610114 B CN 104610114B CN 201510075722 A CN201510075722 A CN 201510075722A CN 104610114 B CN104610114 B CN 104610114B
- Authority
- CN
- China
- Prior art keywords
- compound
- glucose
- glucokinase
- diabetes
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 71
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 claims description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 abstract description 33
- 102000030595 Glucokinase Human genes 0.000 abstract description 32
- 239000012190 activator Substances 0.000 abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 36
- 239000008103 glucose Substances 0.000 description 36
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 238000000605 extraction Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- -1 Exedin) Chemical class 0.000 description 4
- 102000005548 Hexokinase Human genes 0.000 description 4
- 108700040460 Hexokinases Proteins 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 2
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 0 COc1c(CSC(*)NCC(NCCC2CC(CCC3)CC3C2)=O)cccc1 Chemical compound COc1c(CSC(*)NCC(NCCC2CC(CCC3)CC3C2)=O)cccc1 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- IFHNXJZVURNBJS-UHFFFAOYSA-N CC(CCNC(CNC(SCc(cc1)ccc1OC)=S)=O)CC1C(CC2)C2C1 Chemical compound CC(CCNC(CNC(SCc(cc1)ccc1OC)=S)=O)CC1C(CC2)C2C1 IFHNXJZVURNBJS-UHFFFAOYSA-N 0.000 description 1
- HHXRBRBGKOPDQH-UHFFFAOYSA-N CCOc1ccccc1CSC(NCC(NC1(CC(C2)C3)CC3CC2C1)=O)=S Chemical compound CCOc1ccccc1CSC(NCC(NC1(CC(C2)C3)CC3CC2C1)=O)=S HHXRBRBGKOPDQH-UHFFFAOYSA-N 0.000 description 1
- RTGNFCWPPZXLCA-UHFFFAOYSA-N COc1cc(CSC(NCC(NC2(C3)CC(C4)CC3C4C2)=O)=S)ccc1 Chemical compound COc1cc(CSC(NCC(NC2(C3)CC(C4)CC3C4C2)=O)=S)ccc1 RTGNFCWPPZXLCA-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 101001083189 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) Hexokinase-1 Proteins 0.000 description 1
- 101000840556 Oryza sativa subsp. japonica Hexokinase-4, chloroplastic Proteins 0.000 description 1
- 101000840634 Oryza sativa subsp. japonica Hexokinase-5 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the pharmaceutical field relevant to diabetes B. Specifically, the present invention relates to N-diamantane amides glucokinase activators, its preparation method and in the application prepared in diabetes B medicine that a class alkoxyphenyl radical replaces.Wherein, R1It is selected from C1-C3Alkyl.
Description
Technical field
The present invention relates to the pharmaceutical field of the treatment of diabetes B. More particularly, the present invention relates to N-diamantane amides glucokinase activators, its preparation method and the purposes in pharmacy that diabetes B has a class alkoxyphenyl radical of therapeutic action replace.
Background technology
Diabetes comprise a series of syndrome, it is characterized by health and can not produce enough Regular Insulin or normally use Regular Insulin. Most diabetic subject can be divided into insulin-dependent diabetes mellitus (IDDM) or non insulin dependent diabetes (NIDDM) clinically. The diabetes of nearly all type all reduce due to concentration in insulin secretion and blood or the reaction of Regular Insulin is reduced (insulin resistant) by tissue, and this raises relevant with hormone (the female's mouth glucagon) level contrary with insulin action usually. These abnormal conditions make carbohydrate, lipid and Proteometabolism change. This syndrome be masked as hyperglycemia, other complication can comprise cardiovascular disorder, retinopathy, neural pathology, ephrosis, tetter and gastroparesis.
The major objective treating often kind of this kind of illness reduces and control glucose level. In insulin-dependent diabetes (IDDM), the reduction of hyperglycemia can reduce generation (DiabetesControlandComplicationsTrialResearchGroup, NewEnglandJ.Med., 1993 of the adjoint complication of many IDDM, 329,977-986). Such as, tightly control that glucose level can make that the machine nethike embrane of each IDDM patient is sick by the insulinize of high strength, the generation of ephrosis and neural pathology reduce more than 50%. These find to show that together with the pathology similarity seen in IDDM with NIDDM control glucose level can produce similar benefit (AmericanDiabetesAssociation in NIDDM patient, DiabetesCare, 1998,21, S88-90).
Attempt the method for several treatment hyperglycemia. Type i diabetes patient accepts Regular Insulin. In type ii diabetes patient, pancreas can excreting insulin, but its amount is not enough to overcome inherent insulin resistant disease. Give medicine such as two first pair orphan, glitazone and can relax political affairs insulin resistance at least partly, but these medicines can not promote insulin secretion. According to the show, insulin secretion is promoted by affecting ionic channel with the treatment of some sulfonylurea, but, the Regular Insulin caused by such medicine be not glucose dependency or or even glucose-sensitive, in fact this kind for the treatment of can increase the risk of obvious hypoglycemia. By incretin mechanism, DPP-IV inhibitor, such as GLP or GLP analogue (such as Exedin), promotes that cAMP secretes in �� cell, gives this kind of medicine and can promote that Regular Insulin discharges with glucose-dependent fashion. But, even if adopting these effectively to treat, or the glucose level being difficult to tight control NIDMM patient makes the guilding principle that it meets America Diabetes association, club is recommended. Hence, it is highly desirable to the novel method for the treatment of of glycemic control can fully be carried out.
The possible method of glycemic control comprises raising glucose from the clearance rate blood and this rate accelerating glucose stock or utilization. Glucose enters most cells by specific translocator, and wherein glucose is phosphorylated formation G-6-P in by the reaction of hexokinase catalysis. In cell, G-6-P has one of several destiny: be degraded by glycolytic pathway, is converted into soup former, or oxidized by pentose-phosphate pathway.
Glucokinase (GK) is one of the Mammals hexokinase of Four types (hexokinase IV), plays an important role in glucostasis. Glucokinase is mainly arranged in liver and pancreatic beta cell, the wherein expressed glucokinase having several types: due to different montage modes, and these types are different in the amino acid whose sequence of 15N end, but their enzymatic property is substantially identical. Glucokinase is also at the neuron expression of hypothalamus.
Different from the enzymic activity of other three kinds of hexokinase (1, II, III), they just reach capacity at below glucose concn 1mM, and the Km of glucose is 8mM by glucokinase, and it is close to physiological glucose level (5mM). Therefore, under relatively low dextrose level, compared with in liver, glucose is utilized in brain, muscle and other external application tissue quickly and is transformed instead of glucokinase by oneself sugar one by one. Under higher glucose level, such as (after the meal glucose level can more than 10-15mM) after the meal or during supernutrition, glucose metabolism acceleration in liver and pancreas of glucokinase mediation. In addition, hexokinase I, II and III are suppressed by the G-6-P of high density, glucose utilization rate reduce, even and if under high-caliber glucose phosphate, glucokinase can continue the utilization of catalysis glucose.
In the tissue expressing glucokinase, it plays a part extremely important in glucose uptake and application: in �� cell, the required signal of the generation insulin releasing of G-6-P, in hypothalamus, glucose-phosphoric acid as full food signal and may promote the secretion of incretin, in liver, the G-6-P generated by glucokinase effect is as the mechanism by saving as glycosuria process excessive glucose. In liver cell and pancreatic beta-cell, the glucose phosphorylation of glucokinase catalysis act as the rate limiting reaction of glycolysis-. In liver, glucokinase determines the speed of glucose uptake and Glycogen synthesis, and it also is considered as regulating the various necessary material of glucose-sensitive gene. In liver and pancreatic beta cell, glucokinase can limit the speed of glucose utilization, and therefore it regulates the main component from the glycogen storage �� cells secrete insulin and liver. And control the element secretion of political affairs islands and control glycogen storage just diabetes lack. The theoretical importance of glucokinase in diabetes is supported in the research that hereditary colony and the heredity of NIDDM animal model are handled. Glucokinase sudden change is kinase whose relatively low activity form is cause teenager's youth patients with type �� DM occurring. On the contrary, the people of glucokinase activation sudden change not easily suffers from hyperglycemia, and the secretion increasing Regular Insulin comes response glucose tolerance examination (glucosechallenge) (Gloyn, A.L, etal., Diabetes, 2003,52,2433-2440; Glaser, B., etal., NewEnglandJ.Med, 1998,338,226-230). Equally, reported that NIDDM patient has abnormal low dextrose kinase activity. In addition, the overexpression of glucokinase in the diet type (dietary) or genotype (genetic) animal model of diabetes can stop, alleviate or reverse the process of the pathology symptom in this disease. Due to these reasons, pharmaceutical industries oneself at the compound seeking to activate glucokinase.
The carbamovl, the assorted benzyl carbamyl of replacement, the phenyl carbamyl of replacement and the heteroaryl carboxamides based compound of replacement that replace have been disclosed as glucokinase activators. see: WO03/000267, WO03/015774, WO04/045614, WO04/046139, WO05/04480, WO05/054200, WO05/054233, WO05/044801, WO05/056530, WO03/080585, WO04/076420, WO04/081001, WO04/063194, WO04/050645, WO03/055482, WO04/002481, WO05/066145, WO04/072031, WO04/072066, WO00/058293, WO03/095438, WO01144216, WO011083465, WO01/083478, WO01/085706, WO01/085707, WO02/008209, WO02/014312, WO02/046173, WO02/048106, WO03/095438, WO04/031179 and WO04/052869. these compounds can reduce the Km of glucose and/or increase the V of glucokinasemax. Owing to not yet there being the glucokinase activators of list marketing at present, therefore still need a series of glucokinase activators that the Km of glucose suitably can be reduced to 2-5mM under lower activator concentration.
The present invention discloses the N-diamantane amides glucokinase activators that a class alkoxyphenyl radical replaces, and these compounds can be used for preparing the medicine for the treatment of diabetes B.
Summary of the invention
It is an object of the present invention to provide the glucokinase activators of a kind of excellent activity with general formula I.
It is a further object to provide the method that preparation has the compound of general formula I.
It is also another object of the present invention to provide the application of the compound containing general formula I in treatment diabetes B.
Now content of the present invention is specifically described by object in conjunction with the present invention.
The compound that the present invention has general formula I has following structural formula:
Wherein, R1It is selected from C1-C3Alkyl.
Preferred following compound of Formula I,
Compound of Formula I of the present invention is synthesized by following route:
The glycine III that Compound I I and Boc (tertiary butoxy carbonyl) protects condensation under DCC exists generates IV; Boc protecting group is sloughed in compound IV acid treatment, generates V; Compound V first in the presence of a base with CS2Reaction is then reacted with compound VI again, obtains product I; Wherein, X is selected from Cl, Br, I, R1Regularly as previously mentioned.
Compound of Formula I of the present invention has glucokinase activation, can be used as the medicine of effective constituent for the preparation of diabetes B. The activity of compound of Formula I of the present invention is verified by receptor binding assays.
The compound of Formula I of the present invention is effective in quite wide dosage range. The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times. The actual dosage taking compound of Formula I of the present invention can be determined according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated. It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention. Those skilled in the art all should within the protection domain required by the application's claim according to the various changes that the teachings of the present invention is made.
The synthesis of embodiment 1 Compound I-1
A. the synthesis of compound IV-1
Compound I I-11.51g (10mmol) and compound III 1.75g (10mmol) is dissolved in the THF of 20mL drying, stirred at ambient temperature, add N, N'-dicyclohexyl carbodiimide (DCC) 2.48g (12mmol) and 0.50g4-Dimethylamino pyridine (DMAP), then room temperature for overnight, TLC detection reaction completes. After having reacted, pour in 100mL frozen water toward reaction mixture, stir, it may also be useful to the CH of 50mL �� 32Cl2Extraction, merges extraction phase, successively with 1% dilute hydrochloric acid and salt water washing, and anhydrous sodium sulfate drying. Taking out and filter siccative, filtrate is steamed dry on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=309 ([M+H]+)��
B. the synthesis of compound V-1
Compound IV-12.16g (7mmol) is dissolved in 10mL methylene dichloride, stirred at ambient temperature, then adds in 5mL trifluoroacetic acid, room temperature for overnight, and TLC shows reaction to be completed. After having reacted, pour in 100mL frozen water toward reaction mixture, stir, it may also be useful to the CH of 50mL �� 32Cl2Extraction, merges extraction phase, successively with saturated sodium bicarbonate solution and salt water washing, and anhydrous sodium sulfate drying. Taking out and filter siccative, filtrate is steamed dry on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid, ESI-MS, m/z=209 ([M+H]+)��
C. the synthesis of Compound I-1
Compound V-10.83g (4mmol) is dissolved in the THF of 10mL drying, and ice-water bath cooling is lower stirs, and slowly adds the CS that 0.46g (6mmol) is dry in batches2, to stir, then add NaH0.40g (10mmol, purity 60%), then stirred at ambient temperature 5 hours, obtain a lark soup compound. Adding VI-11.01g (5mmol), then room temperature for overnight, TLC checks that reaction completes. After having reacted, carefully pour in 100mL frozen water toward reaction mixture, stir, it may also be useful to the CH of 50mL �� 32Cl2Extraction, merges extraction phase, uses salt water washing, anhydrous sodium sulfate drying. Taking out and filter siccative, filtrate is steamed dry on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-1, white solid, ESI-MS, m/z=405 ([M+H]+)��
The synthesis of embodiment 2 reference compound D-1
A. the synthesis of compound IV-1
Compound I I-11.51g (10mmol) and compound III 1.75g (10mmol) is dissolved in the THF of 20mL drying, stirred at ambient temperature, add N, N'-dicyclohexyl carbodiimide (DCC) 2.48g (12mmol) and 0.50g4-Dimethylamino pyridine (DMAP), then room temperature for overnight, TLC detection reaction completes. After having reacted, pour in 100mL frozen water toward reaction mixture, stir, it may also be useful to the CH of 50mL �� 32Cl2Extraction, merges extraction phase, successively with 1% dilute hydrochloric acid and salt water washing, and anhydrous sodium sulfate drying. Taking out and filter siccative, filtrate is steamed dry on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid, ESI-MS, m/z=309 ([M+H]+)��
B. the synthesis of compound V-1
Compound IV-12.16g (7mmol) is dissolved in 10mL methylene dichloride, stirred at ambient temperature, then adds in 5mL trifluoroacetic acid, room temperature for overnight, and TLC shows reaction to be completed. After having reacted, pour in 100mL frozen water toward reaction mixture, stir, it may also be useful to the CH of 50mL �� 32Cl2Extraction, merges extraction phase, successively with saturated sodium bicarbonate solution and salt water washing, and anhydrous sodium sulfate drying. Taking out and filter siccative, filtrate is steamed dry on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid, ESI-MS, m/z=209 ([M+H]+)��
C. the synthesis of Compound D-1
Compound V-10.83g (4mmol) is dissolved in the THF of 10mL drying, and ice-water bath cooling is lower stirs, and slowly adds the CS that 0.46g (6mmol) is dry in batches2, to stir, then add NaH0.40g (10mmol, purity 60%), then stirred at ambient temperature 5 hours, obtain a lark soup compound. Adding VI-2 (cylite) 0.86g (5mmol), then room temperature for overnight, TLC checks that reaction completes. After having reacted, carefully pour in 100mL frozen water toward reaction mixture, stir, it may also be useful to the CH of 50mL �� 32Cl2Extraction, merges extraction phase, uses salt water washing, anhydrous sodium sulfate drying. Taking out and filter siccative, filtrate is steamed dry on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound D-1, white solid, ESI-MS, m/z=375 ([M+H]+)��
Embodiment 3-7
With reference to embodiment 1 method, synthesize compound listed in Table.
The external activation to glucokinase of embodiment 8 compound
Extracorporeal glucose kinases is tested
The external activity of the glucokinase activators of the present invention is evaluated in two independent tests: use EC50Test to evaluate the effect of each compound under glucose fixing, physiology related concentrations, and the glucose S under the compound of fixing, closely saturated (if may) concentration0.5Test is to evaluate its Vm and S for glucose0.5Effect. These tests for each, glucokinase is by, in the test macro containing NAD+ and the coupling of glucose 6-phosphate dehydrogenase, monitoring the increase of optical density at 340nm and estimate. Test, at 30 DEG C, utilizes the microplate reader (absorbanceplatereader) of thermostatic control and transparent, 96 holes, flat, polystyrene board (Costar3695, Coming) to carry out. Each 50 �� L test mixing thing contains 10mMK+MOPS, pH7.2,2mMMgCl2, 50mMKCl, 0.01%TritonX-100,2%DMSO, 1mMDTT, 1mMATP, 1mMNAD+, 5U/mL glucose 6-phosphate dehydrogenase, about 5nM human glocose swashs glucose and the test compounds of dark and (depending on test) different concns. In the optical density of 340nm dynamic monitoring 5 minute period (10s/ circulation), and speed (rate) estimated by the oblique soldier of the straight line of matching raw data.
Glucokinase EC50Test:
For this test, glucose concn is fixed on 5mM, and comparison or test compounds are about 2.5nM as high dosage 50 ��Ms to low dosage taking 10 points (l-point), 3 times of dilution series and usual scope. By standard, 4 parameters logarithmic model matching raw data (speed is compared to compound concentration):
Y=A+ (B-A)/[1+C/x]D
Wherein x is the concentration of compound, and y is the speed of estimation, A and B is respectively lower asymptotic line and upper asymptotic line, and C is EC50, D is Hill slope. EC50The mid point being defined as between asymptotic line and lower asymptotic line or flex point. The EC of some compound in the present invention50Data are as shown in the table:
| Compound | EC50(nM) |
| Compound I-1 | 7.3 |
| Reference compound D-1 | 21.6 |
| Compound I-3 | 8.2 |
| Compound I-4 | 7.8 |
| Compound I-5 | 10.7 |
| Compound I-6 | 12.4 |
| Compound I-7 | 11.2 |
Glucose S0.5Test:
For this test, the concentration of comparison or test compounds is fixed on or close to saturation concentration, if possibility, is generally 50 ��Ms, and glucose concn is from 80 to about 0.16mM, through 10 points, 2 times of dilution series changes. Use with for EC50Test 4 identical parameter logarithmic models and measure relevant kinetic parameter. In this test, the definition for variable and parameter is similar, and except x represents the concentration of glucose, B is the speed (Vm) of saturated glucose, and C is the S of glucose0.5(under the concentration of Vm/2 glucose) and D are Hill coefficient. The S of some compound in the present invention0.5Data are as shown in the table:
| Compound | S0.5(mM) |
| Compound I-1 | 1.8 |
| Reference compound D-1 | 4.1 |
| Compound I-3 | 2.4 |
| Compound I-4 | 2.7 |
| Compound I-5 | 3.2 |
| Compound I-6 | 3.6 |
| Compound I-7 | 3.1 |
The determination of activity result of above-mentioned two tables shows, the compound of the present invention is strong glucokinase activators, it is possible to be used for preparing the medicine for the treatment of diabetes B.
Claims (4)
1. the compound with general formula I,
Wherein, R1It is selected from C1-C3Alkyl.
2. the compound of Formula I that claim 1 defines, is selected from:
3. synthesize the method for arbitrary the defined compound belonging to general formula I of claim 1-2:
The glycine III that Compound I I and Boc (tertiary butoxy carbonyl) protects condensation under DCC exists generates IV; Boc protecting group is sloughed in compound IV acid treatment, generates V; Compound V first in the presence of a base with CS2Reaction is then reacted with compound VI again, obtains product I; Wherein, X is selected from Cl, Br, I, R1Definition as arbitrary in claim 1-2 as described in.
4. the application of the compound of Formula I that one of claim 1-2 defines in preparation treatment diabetes B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510075722.8A CN104610114B (en) | 2015-02-12 | 2015-02-12 | The N-diamantane amides that one class alkoxyphenyl radical replaces and purposes thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510075722.8A CN104610114B (en) | 2015-02-12 | 2015-02-12 | The N-diamantane amides that one class alkoxyphenyl radical replaces and purposes thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104610114A CN104610114A (en) | 2015-05-13 |
| CN104610114B true CN104610114B (en) | 2016-06-01 |
Family
ID=53144802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510075722.8A Expired - Fee Related CN104610114B (en) | 2015-02-12 | 2015-02-12 | The N-diamantane amides that one class alkoxyphenyl radical replaces and purposes thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104610114B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080585A1 (en) * | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| EP1532980A1 (en) * | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| GB0510852D0 (en) * | 2005-05-27 | 2005-07-06 | Astrazeneca Ab | Chemical compounds |
| GB0514175D0 (en) * | 2005-07-09 | 2005-08-17 | Astrazeneca Ab | Chemical compounds |
| GB0516300D0 (en) * | 2005-08-09 | 2005-09-14 | Astrazeneca Ab | Chemical compounds |
| GT200600428A (en) * | 2005-09-30 | 2007-05-21 | ORGANIC COMPOUNDS |
-
2015
- 2015-02-12 CN CN201510075722.8A patent/CN104610114B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104610114A (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Veldman et al. | Successful treatment of molybdenum cofactor deficiency type A with cPMP | |
| CN101484440A (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| CN101484441A (en) | Modulators of metabolism and the treatment of disorders related thereto | |
| CN102942562B (en) | Benzimidazole derivative, and preparation method and application thereof | |
| CN104610112B (en) | N-phenyl diamantane amides glucokinase activators, preparation method and its usage | |
| CN104693085B (en) | Containing N-phenyl diamantane amides, the Its Preparation Method And Use of halogeno-benzene | |
| CN104610114B (en) | The N-diamantane amides that one class alkoxyphenyl radical replaces and purposes thereof | |
| CN104628616B (en) | Containing N-diamantane amides, the Preparation Method And The Use of p-nitrophenyl | |
| CN104610115B (en) | A kind of N-phenyl diamantane amides containing p-nitrophenyl and purposes | |
| CN104693084B (en) | The N-diamantane amides of nitrile group-containing phenyl, Preparation Method And The Use | |
| CN104592073B (en) | One class is containing N-diamantane amides, the purposes of alcoxyl benzene | |
| CN104628617B (en) | N-diamantane amides glucokinase activators, preparation method and its usage | |
| CN104610113B (en) | A kind of N-phenyl diamantane amides of nitrile group-containing benzene and purposes | |
| CN104628615B (en) | Containing N-diamantane amides, the Its Preparation Method And Use of halogeno-benzene | |
| CN104557698A (en) | Glucokinase activating agent containing quinolyl and alkoxylphenyl structure and application thereof | |
| CN104610242A (en) | Compound containing glucosamide pyridine and alkoxypyrazine structure and application of compound | |
| CN104610241A (en) | Glucokinase activator containing glucosamide and pyridine structure and application of glucokinase activator | |
| CN104592214A (en) | Compound containing glucosamide pyridine and alkoxy pyrazinyl structure and application thereof | |
| CN104610243A (en) | Glucokinase activator containing glucosamide and pyridine structure and application thereof | |
| CN104672218A (en) | Glucokinase activator containing glucosamide structure, preparation method and application of glucokinase activator to treatment of type II diabetes mellitus | |
| CN104672219A (en) | Glucokinase activators containing glucosamide structure and application thereof | |
| CN104557700A (en) | Glucokinase activating agent containing nitrile quinoline structure and application thereof | |
| CN104672133A (en) | Glucokinase activator containing quinoline structure as well as preparation method and application thereof | |
| CN104610143A (en) | Glucokinase activator containing nitroquinoline structure and application of glucokinase activator | |
| CN104892505A (en) | Glucokinase activator with halogenated quinoline and preparing method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Alkoxyphenyl-substituted N-adamantane amide type compound and application thereof Effective date of registration: 20170816 Granted publication date: 20160601 Pledgee: Guangdong Nanhai Rural Commercial Bank branch branch of Limited by Share Ltd. Pledgor: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Registration number: 2017990000756 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190604 Granted publication date: 20160601 Pledgee: Guangdong Nanhai Rural Commercial Bank branch branch of Limited by Share Ltd. Pledgor: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Registration number: 2017990000756 |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20190909 Address after: 064200 Second Floor of Commercial Building 101, Huayu District, Zunhua City, Tangshan City, Hebei Province Patentee after: Hebei Chenbikang Health Management Co.,Ltd. Address before: Chancheng district has 528000 Taiwan public in Guangdong province Foshan City No. 32 first floor 1636, shop No. 1637 Patentee before: FOSHAN SAIWEISI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201014 Address after: 064200 No. 11, Block B, Fulidi Shang, Zunhua City, Tangshan City, Hebei Province Patentee after: Zunhua Penghai Mingrui Network Technology Co.,Ltd. Address before: 064200 Second Floor of Commercial Building 101, Huayu District, Zunhua City, Tangshan City, Hebei Province Patentee before: Hebei Chenbikang Health Management Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201231 Address after: 221000 Shengqiang Road, Xinhe Town, Pizhou City, Xuzhou City, Jiangsu Province Patentee after: Jiangsu jinyufeng New Material Co.,Ltd. Address before: 064200 No.11, block B, Fuli bottom business, Zunhua City, Tangshan City, Hebei Province Patentee before: Zunhua Penghai Mingrui Network Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160601 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |